Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Evenity

Roche Basel Switzerland

NICE backs Roche’s Gazyvaro after initial rejection

An undisclosed discount swayed the cost-effectiveness body

- PMLiVE

Roche’s lung drug Esbriet reserved for worse cases, says NICE

Boehringer Ingelheim’s Ofev subject to same conditions

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

- PMLiVE

UCB supports social network for SpA patients

MySpondylitisTeam is launched by MyHealthTeams

- PMLiVE

NICE backs trial of online and mobile depression programme

First digital psychological therapy briefing covers Servier and Gaia's Deprexis

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

Biogen Idec building

NICE finally starts review of Biogen’s Spinraza for SMA

Will evaluate the treatment based on its Single Technology Appraisal process

- PMLiVE

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment

- PMLiVE

NICE backs GSK’s €594k gene therapy for rare disease

The treatment offers 'bubble baby' patients an alternative to a stem cell transplant

National Institute for Health and Care Excellence NICE logo

NICE to look again at Pfizer’s Besponsa after appeal

The blood cancer medicine was originally turned down on cost-effectiveness grounds

Novartis day

Novartis’ Extavia evades NICE restrictions on MS drugs

But Avonex, Plegridy, Betaferon, Rebif and Copaxone are set to be turned down

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links